Form 4: Director Karen Prange Sells 3,000 AtriCure Shares

AtriCure, Inc. Director Karen Prange reported the sale of 3,000 shares of common stock at a weighted average price of $28.65.

Summary

• Director Karen Prange sold 3,000 shares of AtriCure, Inc. (ATRC) common stock.
• The transaction occurred on May 20, 2026.
• The shares were sold at a weighted average price of $28.65 per share, with individual trades ranging from $28.60 to $28.76.
• Following this transaction, the reporting person retains beneficial ownership of 26,373 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a standard regulatory disclosure of an insider transaction without accompanying negative or positive strategic news.

Positives

• The transaction represents a routine divestment by an insider rather than a complete exit from the company.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in near-term share price appreciation.

Risks

• Market volatility affecting the share price of AtriCure, Inc.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that insider sales are common occurrences for directors and executives for personal financial planning and do not necessarily reflect a change in the company's fundamental business outlook.

Comparison to Industry Standards

• Insider sales of this volume are standard practice for board members and do not deviate from typical corporate governance patterns in the medical device sector.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale represents a small portion of the director's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

AtriCure, ATRC, Insider Trading, Form 4, Karen Prange, Stock Sale